BioAge Labs (BIOA) Competitors $4.63 -0.17 (-3.54%) As of 07/18/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsOwnershipSEC FilingsTrendsBuy This Stock BIOA vs. STOK, DNTH, TNGX, PHAT, XNCR, IOVA, UPB, RLAY, CDXC, and EOLSShould you be buying BioAge Labs stock or one of its competitors? The main competitors of BioAge Labs include Stoke Therapeutics (STOK), Dianthus Therapeutics (DNTH), Tango Therapeutics (TNGX), Phathom Pharmaceuticals (PHAT), Xencor (XNCR), Iovance Biotherapeutics (IOVA), Upstream Bio (UPB), Relay Therapeutics (RLAY), ChromaDex (CDXC), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. BioAge Labs vs. Its Competitors Stoke Therapeutics Dianthus Therapeutics Tango Therapeutics Phathom Pharmaceuticals Xencor Iovance Biotherapeutics Upstream Bio Relay Therapeutics ChromaDex Evolus Stoke Therapeutics (NASDAQ:STOK) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk. Which has higher valuation and earnings, STOK or BIOA? BioAge Labs has lower revenue, but higher earnings than Stoke Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$36.56M19.74-$88.98M$0.7916.73BioAge LabsN/AN/A-$71.11MN/AN/A Is STOK or BIOA more profitable? Stoke Therapeutics has a net margin of 26.33% compared to BioAge Labs' net margin of 0.00%. Stoke Therapeutics' return on equity of 19.08% beat BioAge Labs' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.33% 19.08% 15.72% BioAge Labs N/A N/A N/A Does the media favor STOK or BIOA? In the previous week, Stoke Therapeutics had 8 more articles in the media than BioAge Labs. MarketBeat recorded 8 mentions for Stoke Therapeutics and 0 mentions for BioAge Labs. Stoke Therapeutics' average media sentiment score of 0.44 beat BioAge Labs' score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Stoke Therapeutics Neutral BioAge Labs Neutral Do analysts recommend STOK or BIOA? Stoke Therapeutics currently has a consensus price target of $25.80, indicating a potential upside of 95.16%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29BioAge Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryStoke Therapeutics beats BioAge Labs on 10 of the 11 factors compared between the two stocks. Get BioAge Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOA vs. The Competition Export to ExcelMetricBioAge LabsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$165.99M$779.97M$2.16B$9.40BDividend YieldN/A4.84%2.59%4.04%P/E RatioN/A1.4122.1319.77Price / SalesN/A24.93101.5588.91Price / CashN/A19.5628.2128.17Price / Book0.517.0557.615.69Net Income-$71.11M-$3.55M-$121.56M$257.97M7 Day PerformanceN/A-0.30%0.58%1.92%1 Month PerformanceN/A2.56%2.61%12.82%1 Year PerformanceN/A4.43%24.20%19.22% BioAge Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOABioAge LabsN/A$4.63-3.5%N/AN/A$165.99MN/A0.00N/ASTOKStoke Therapeutics4.2276 of 5 stars$11.86-1.5%$24.75+108.7%-2.7%$647.52M$190.91M15.01100Analyst ForecastGap UpDNTHDianthus Therapeutics1.3415 of 5 stars$20.06-2.7%$53.00+164.2%-23.2%$645.13M$6.52M-6.9780TNGXTango Therapeutics1.6039 of 5 stars$5.93-2.9%$12.20+105.7%-27.0%$642.78M$42.07M-4.8690PHATPhathom Pharmaceuticals4.1728 of 5 stars$9.18-5.3%$17.50+90.6%-27.4%$640.89M$81.86M-1.75110XNCRXencor4.1096 of 5 stars$8.83-4.8%$28.00+217.1%-53.1%$628.44M$127.23M-2.89280IOVAIovance Biotherapeutics4.7279 of 5 stars$1.87-3.1%$12.22+553.6%-72.0%$624.46M$164.07M-1.51500Analyst RevisionGap UpUPBUpstream BioN/A$11.48-3.0%$56.50+392.2%N/A$617.56M$2.37M0.0038RLAYRelay Therapeutics2.6588 of 5 stars$3.60-3.5%$17.67+390.7%-59.3%$617.20M$7.68M-1.61330CDXCChromaDexN/AN/A$9.03+∞N/A$611.50M$99.60M787.29120EOLSEvolus3.9965 of 5 stars$9.48-2.6%$23.75+150.5%-23.1%$611.23M$266.27M-10.65170 Related Companies and Tools Related Companies STOK Alternatives DNTH Alternatives TNGX Alternatives PHAT Alternatives XNCR Alternatives IOVA Alternatives UPB Alternatives RLAY Alternatives CDXC Alternatives EOLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOA) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAge Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAge Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIOA Stock Alerts